These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24821853)

  • 21. Psoas abscess during treatment with intravenous tocilizumab in a patient with rheumatoid arthritis: a case-based review.
    Vajdić ID; Štimac G; Pezelj I; Mustapić M; Grazio S
    Rheumatol Int; 2021 Apr; 41(4):819-825. PubMed ID: 33576887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tocilizumab: a review of its use in the management of rheumatoid arthritis.
    Oldfield V; Dhillon S; Plosker GL
    Drugs; 2009; 69(5):609-32. PubMed ID: 19368420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Tocilizumab in rheumatoid arthritis. Interleukin 6 as a new target].
    Heinzl S
    Med Monatsschr Pharm; 2008 Dec; 31(12):450-3. PubMed ID: 19133593
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis.
    Zhang X; Peck R
    Expert Rev Clin Pharmacol; 2011 Sep; 4(5):539-58. PubMed ID: 22114882
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serious herpes zoster in rheumatoid arthritis under anti-interleukin-6 receptor antibody.
    Kubandova Z; Mathieu S; Pourtier C; Soubrier M
    Joint Bone Spine; 2010 Dec; 77(6):623-4. PubMed ID: 20851657
    [No Abstract]   [Full Text] [Related]  

  • 26. Serological biomarkers of joint tissue turnover predict tocilizumab response at baseline.
    Bay-Jensen AC; Byrjalsen I; Siebuhr AS; Christiansen C; Platt A; Karsdal MA
    J Clin Rheumatol; 2014 Sep; 20(6):332-5. PubMed ID: 25160020
    [No Abstract]   [Full Text] [Related]  

  • 27. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    McLaughlin M; Östör A
    Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progressive Multifocal Leukoencephalopathy during Tocilizumab Treatment for Rheumatoid Arthritis.
    Anada M; Tohyama M; Oda Y; Kamoshima Y; Amino I; Nakano F; Miyazaki Y; Akimoto S; Minami N; Kikuchi S; Terae S; Niino M
    Intern Med; 2020 Aug; 59(16):2053-2059. PubMed ID: 32448834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [IL-6 blockade].
    Kaneko Y; Takeuchi T
    Nihon Rinsho; 2016 Jun; 74(6):963-7. PubMed ID: 27311186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical efficacy of tocilizumab in rheumatoid arthritis.
    Mircic M; Kavanaugh A
    Drugs Today (Barc); 2009 Mar; 45(3):189-97. PubMed ID: 19436841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis.
    Protogerou AD; Zampeli E; Fragiadaki K; Stamatelopoulos K; Papamichael C; Sfikakis PP
    Atherosclerosis; 2011 Dec; 219(2):734-6. PubMed ID: 21968316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pancolitis during etanercept treatment of rheumatoid arthritis relapsing on the administration of further two TNF-alpha inhibitors.
    Actis GC; Lagget M; Pellicano R; Rosina F
    Int J Colorectal Dis; 2012 Apr; 27(4):547-8. PubMed ID: 21656142
    [No Abstract]   [Full Text] [Related]  

  • 33. [IL-6 inhibitors for treatment of rheumatoid arthritis].
    Nishimoto N
    Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2413-7. PubMed ID: 19149037
    [No Abstract]   [Full Text] [Related]  

  • 34. The role of tocilizumab in the management of rheumatoid arthritis.
    Ash Z; Emery P
    Expert Opin Biol Ther; 2012 Sep; 12(9):1277-89. PubMed ID: 22849354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment--data from randomized clinical trials.
    Kavanaugh A
    Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S16-20. PubMed ID: 17708740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tocilizumab, an anti-interleukin-6 receptor antibody, efficiently ameliorates persistent joint inflammation in rheumatoid arthritis.
    Hirabayashi Y
    Mod Rheumatol; 2021 Jan; 31(1):70-79. PubMed ID: 32342712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
    Sagawa A
    Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tocilizumab in the treatment of adult rheumatoid arthritis.
    Sanmartí R; Ruiz-Esquide V; Bastida C; Soy D
    Immunotherapy; 2018 Mar; 10(6):447-464. PubMed ID: 29495891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psoriasis onset with tocilizumab treatment for rheumatoid arthritis.
    Wendling D; Letho-Gyselinck H; Guillot X; Prati C
    J Rheumatol; 2012 Mar; 39(3):657. PubMed ID: 22383356
    [No Abstract]   [Full Text] [Related]  

  • 40. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.
    Nishimoto N; Miyasaka N; Yamamoto K; Kawai S; Takeuchi T; Azuma J
    Ann Rheum Dis; 2009 Oct; 68(10):1580-4. PubMed ID: 19019888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.